About Us
MetaVia is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia is currently developing DA-1726 for the treatment of obesity, and is developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH).
DA-1726 is a novel, dual oxyntomodulin (OXM) analog agonist that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR), for once-a-week injection. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. DA-1241 is a novel G-protein-coupled receptor 119 (GPR119) agonist that promotes the release of key gut peptides GLP-1, GIP, and PYY. In pre-clinical studies, DA-1241 demonstrated a positive effect on liver inflammation, lipid metabolism, weight loss, and glucose metabolism, reducing hepatic steatosis, hepatic inflammation, and liver fibrosis, while also improving glucose control.
Our strategic partner and the largest investor, Dong-A ST Co. Ltd., is part of the Dong-A Socio Group of companies established in 1932 and based in South Korea. MetaVia has the full support of Dong-A ST’s Research center, providing the company with access to R&D, scientific and CMC expertise.
management TEAM
Board of Directors
Scientific Advisory Board
Roy Freeman, MD
Angela Fitch, MD, FACP, FOMA
Lee Kaplan, MD, Ph.D.
Carel le Roux, MBChB, MSC, FRCP, FRCPath, Ph.D.
Dong-A ST Co., Ltd. Strategic Partnership
MetaVia entered a licensing agreement with Dong-A ST Co., Ltd. and a strategic partnership with one of the largest pharmaceutical group of companies in South Korea; Dong-A Socio Group.
Dong-A Socio Group was founded in 1932 and is the leading Korean pharmaceutical and over-the-counter medicinal products group of companies with capabilities in all aspects of the pharmaceutical industry including drug research from discovery stage, global clinical development, manufacturing small molecules to oligonucleotides and mRNA, marketing and sales of pharmaceutical products and biosimilars, and global logistics. Dong-A ST and Dong-A Socio Group of companies have successfully developed and launched drugs globally and continue to develop clinical candidates. For more information visit en.donga.co.kr.